The Institute is a leading developer and manufacturer of biomedical cell products (BMCP), and treatment methods based on its use.
The Institute’s modern laboratory facilities, equipped and accredited according to international GMP standards, produce more than 14 types of certified BMCP with high functional characteristics. Based on the experience and global trends in the development of cell technologies, in 2010 the IBCE created a production base for obtaining standardized cell transplants with high functional characteristics and organized the production of BMCP, which meets international GMP standards.
THE MAIN SCIENTIFIC DIRECTIONS of Institute:
— molecular and cell biophysics,
— tissue and cell engineering,
— immunology and cell-based immunotherapy,
— virology and vaccine development
— nanotechnologies and nanotoxicology
— algology and plant biology
— drug design.
Currently, the Institute produces 16 certified BMCP out of 7 registered by the Ministry of Health of the Republic of Belarus, being the leading commercial supplier.

該研究所是生物醫學細胞產品（BMCP）及其相關治療方法的領先開發商和製造商。
研究所擁有符合國際GMP標準的現代化實驗室設施，並經過認證，可生產超過14種經認證的高性能BMCP。基於在細胞技術發展方面的經驗和全球趨勢，IBCE於2010年建立了一個生產基地，用於獲取具有高性能的標準化細胞移植物，並組織生產符合國際GMP標準的BMCP。
研究所的主要研究方向：
— 分子與細胞生物物理學；
— 組織與細胞工程；
— 免疫學與細胞免疫療法；
— 病毒學與疫苗研發；
— 奈米科技與奈米毒理學；
— 藻類學與植物生物學；
— 藥物設計。
目前，研究所生產了16種經認證的BMCP，其中7種已在白俄羅斯共和國衛生部註冊，是領先的商業供應商。

IBCE has developed logistic algorithms that make it possible to organize the supply of these high-tech BMCP to almost any healthcare organization in the Belarus, as well as for export.
For scientific organizations and biotechnological companies the Institute offers scientific, practical and commercial cooperation in the field of cell technologies. The accumulated competencies, reputation and infrastructure of Institute provide ample opportunities for mutually beneficial and successful cooperation.
An option for scientific interaction may be a cooperation agreement, which will allow planning joint research projects, conducting educational events and academic exchange programs.

The Institute has a specialized clinic — the Department of Cell Therapy, offering patients a wide range of treatment programs based on cell technologies:
— immunotherapy of oncological diseases using monocytic dendritic cells and cytokine-induced killer lymphocytes;
— orthobiological technologies for joint restoration in degenerative pathologies of the musculoskeletal system using mesenchymal stem cells;
— immunotherapy of autoimmune diseases (Type 1 Diabetes Mellitus and SLE) using tolerogenic dendritic cells and pooled mesenchymal stem cells;
— cell therapy of such severe neurological diseases as multiple sclerosis and Parkinson’s disease in adults, as well as cerebral palsy and epilepsy in children;
— aesthetic bio-reparative technologies for the treatment of alopecia and correction of age-related and cicatricial changes in the skin using follicular stem cells and fibroblasts;
— regenerative ophthalmology (treatment of corneal damage and diseases),
— regenerative urology (treatment of female and male incontinence).
A practical initiative in the segment of cell medical tourism may be the international business project «Affordable Biomedical Technologies». The main idea of the project is to organize medical services for cell therapy for Chinese and Belarusian patients with convenient logistics and affordability.
The Institute has a long-standing and close cooperation with Donghua University (China). Within the framework of this cooperation, a project dedicated to studying the possibility of using nanoparticles in medicine has been successfully implemented. Currently, 3 scientific projects are being carried out aimed at finding effective nanoparticles for the treatment of cancer and ischemic stroke.

IBCE 已開發出物流演算法，能夠將這些高科技骨髓間質幹細胞 (BMCP) 供應給白俄羅斯幾乎所有醫療機構，並用於出口。
研究所為科研機構和生物技術公司提供細胞技術領域的研究、實務和商業合作。研究所累積的專業知識、聲譽和基礎設施為互利共贏的合作提供了充足的機會。
科學研究互動的一種方式是簽訂合作協議，該協議將允許規劃聯合研究計畫、開展教育活動和學術交流計畫。

研究所設有專門的診所－細胞治療科，為患者提供基於細胞技術的多種治療方案：
— 使用單核細胞樹突狀細胞和細胞激素誘導的殺傷淋巴細胞進行腫瘤疾病的免疫治療；
— 使用間質幹細胞進行肌肉骨骼系統退化性病變關節修復的骨生物學技術；
— 使用耐受性樹突狀細胞和混合間質幹細胞進行自體免疫疾病（第1型糖尿病和系統性紅斑狼瘡）的免疫治療；
— 細胞療法治療成人多發性硬化症和帕金森氏症等嚴重神經系統疾病，以及兒童腦性麻痺和癲癇；
— 使用毛囊幹細胞和纖維母細胞治療脫髮、矯正年齡相關性皮膚病變和瘢痕性皮膚病變的美容生物修復技術；
— 再生眼科（治療角膜損傷和疾病）；
— 再生泌尿科（治療女性和男性尿失禁）。
「經濟實惠的生物醫學技術」國際商業計畫是細胞醫療旅遊領域的務實舉措。該計畫的主要理念是為中國和白俄羅斯患者提供便利且價格合理的細胞治療醫療服務。
該研究所與中國東華大學保持長期密切的合作關係。在該合作框架下，一個致力於研究奈米粒子在醫學領域應用可能性的計畫已成功實施。目前，另有三個科學研究計畫正在進行，旨在尋找用於治療癌症和缺血性中風的有效奈米粒子。

Proposals for cooperation in the field of cell engineering and cell/gene therapy:
— Development and study of miscellaneous cell products for medical and veterinary use.
— Production of certified cell products.
— Provision of medical services using cellular technologies.
— Genetic modification of differentiated and stem cells using lentiviral and adenoviral vector systems for the purpose of further use in scientific biomedical research and cell therapy.
— Generation of the induced pluripotent stem cells for biomedical research.
— Genetic therapy of oncological diseases with small interfering RNA (siRNA) and microRNA
— Genome editing of somatic cells using CRISPR/Cas9 technology for research in pharmacology, gene therapy, and the treatment of patients with hereditary diseases
— Laboratory (in vitro) studies of cell products and drugs for gene therapy.

細胞工程和細胞/基因治療領域合作建議：
— 開發和研究用於醫療和獸醫學的各種細胞產品。
— 生產經認證的細胞產品。
— 提供利用細胞技術的醫療服務。
— 利用慢病毒和腺病毒載體系統對分化細胞和幹細胞進行基因改造，進一步用於生物醫學科學研究和細胞治療。
— 產生用於生物醫學研究的誘導性多能幹細胞。
— 利用小幹擾RNA (siRNA) 和microRNA進行腫瘤疾病的基因治療。
— 利用CRISPR/Cas9技術對體細胞進行基因組編輯，用於藥理學研究、基因治療和遺傳性疾病患者的治療。
— 進行用於基因治療的細胞產品和藥物的實驗室（體外）研究。

WeChat: ibce-by